Cardiff Oncology Inc (NASDAQ:CRDF) does about 1.73M shares in volume on a normal day but saw 943551 shares change hands in Tuesday trading. The company now has a market cap of 252.89M USD. Its current market price is $5.66, marking a decrease of -3.74% compared to the previous close of $5.88. The 52 week high reached by this stock is $6.42 whilst the lowest price level in 52 weeks is $0.94.
Cardiff Oncology Inc (CRDF) has a 20-day trading average at $5.41 and the current price is -11.84% off the 52-week high compared with 502.13% distance from its 52-week low. The 50-day simple moving average of the closing price is $3.46 and its 200-day simple moving average is $1.96. If we look at the stock’s price movements over the week, volatility stands at 11.95%, which increases to 14.75% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 62.37 to suggest the stock is neutral.
The consensus objective for the share price is $10.50, suggesting that the stock has a potential upside of 46.1% over the period.
Maxim Group resumed its price target at $30-$20.
Cardiff Oncology Inc (CRDF) stock is up 5.40% over the week and 36.71% over the past month. Its price is 282.43% year-to-date and 278.60% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/30/2023, with the company’s earnings per share (EPS) of -$0.21 above consensus estimates by $0.07. CRDF’s earnings per share are forecast to shrink by -4.30% this year and -8.20% over next year. Expected sales for next quarter are $60k, which analysts say will come at $240k for the current fiscal year and next year at $70k. In addition, estimates put the company’s current quarterly revenue at an average of $50k.
To reach the target analysts have set, the stock logically needs to grow 46.1 percent from here.
Outstanding shares total 44.68M with insiders holding 7.56% of the shares and institutional holders owning 15.17% of the company’s common stock. The company has a return on investment of -58.24% and return on equity of -47.07%. The beta has a value of 1.96. Price to book ratio is 3.63 and price to sales ratio is 516.10.
